Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin

Chemotherapy is widely used for the treatment of ovarian cancer. Since chemotherapy resistance is the major cause of poor prognosis in patients with ovarian cancer, it is important to identify new methods to improve the efficacy of chemotherapy. Minichromosome maintenance complex component 2 (MCM2),...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Minjie, Sun, Jiajun, Xie, Suhong, Zhen, Hui, Wang, Yanchun, Zhong, Ailing, Zhang, Hongqin, Lu, Renquan, Guo, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691261/
https://www.ncbi.nlm.nih.gov/pubmed/31322224
http://dx.doi.org/10.3892/mmr.2019.10477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691261/
https://www.ncbi.nlm.nih.gov/pubmed/31322224
http://dx.doi.org/10.3892/mmr.2019.10477

Ejemplares similares